5-(2-Carboxy-1-ethenyl)-2,2'-bithiophene | 3515-26-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 双噻吩和低聚噻吩
• 英文名称: 5-(2-Carboxy-1-ethenyl)-2,2'-bithiophene
• 英文别名: 3-(5-thiophen-2-ylthiophen-2-yl)prop-2-enoic acid
• CAS: 3515-26-2
• 化学式: C₁₁H₈O₂S₂
• 分子量: 236.3
• InChiKey: HWUXLEJHIBZOHB-UHFFFAOYSA-N

物化性质

• 熔点：
  171 °C
• 沸点：
  425.8±40.0 °C(Predicted)
• 密度：
  1.395±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  93.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,2-联噻吩-5-乙醛 、 丙二酸 、 哌啶 、 盐酸 在 silica gel 、 acetone hexane 作用下， 以 水 、 吡啶 为溶剂， 反应 2.17h， 以From the eluate of acetone/n-hexane (2/5), 2.95 g of product was thus obtained的产率得到5-(2-Carboxy-1-ethenyl)-2,2'-bithiophene
  参考文献：
  名称：

  Medicinal thiophene compounds

  摘要：

  一种治疗炎症的方法，包括向受体内投与以下式子的化合物的有效量：##STR1## 其中m为1-4；而每个A和B，独立地，是H，C.sub.1-7烷基，C.sub.2-7烯基，C.sub.2-7炔基，(CH.sub.2).sub.nCHO，(CH.sub.2).sub.oCOOH，C.sub.1-7烷氧基，C.sub.2-7烷氧基烷基，C.sub.1-7羟基烷基，CN，NO.sub.2，卤素，CH(OR.sup.1).sub.2，CO.R.sup.1，NR.sup.2R.sup.3或其酸盐，CO.NR.sup.2R.sup.3，CHR.sup.1NR.sup.2R.sup.3或其酸盐，CH=NR.sup.2，C.tbd.CR.sup.4，CR.sup.1=CR.sup.5R.sup.6，CO.CH.dbd.CHR.sup.7，CH.dbd.CHR.sup.8或COOR.sup.9；其中n和o，各自独立地为0-4；R.sup.1是C.sub.1-4烷基或C.sub.1-4酰基；每个R.sup.2和R.sup.3，各自独立地为H，C.sub.1-4烷基或C.sub.1-4羟基烷基；R.sup.4为H，C.sub.1-4烷基，C.sub.2-4烯基，COR.sup.2，COOR.sup.10，C.sub.1-4羟基烷基或其酸酯或2-四氢吡喃醚，C.sub.1-4二羟基烷基或其酸酯或2-四氢吡喃醚，C.sub.1-4卤代烷基；OR.sup.1，NHR.sup.7；每个R.sup.5R.sup.6，各自独立地为H，CHO，COR.sup.1，COOH，COOR.sup.9，CN或卤素；R.sup.7为H，C.sub.1-4烷基，2-噻吩基，苯基，单取代苯基或二取代苯基；R.sup.8为COOR.sup.2，CO.CHO，C.sub.1-4羟基烷基或其酸酯或2-四氢吡喃醚；而R.sup.9是H，C.sub.1-4烷基，苯基，单取代苯基，二取代苯基或2-噻吩基。

  公开号：

  US05602170A1

文献信息

• Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
  申请人：sanofi-aventis

  公开号：EP1939180A1

  公开（公告）日：2008-07-02

  The present invention relates to heteroarylacrylamides of the formula I, in which Het, X, Ra, Rb, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及式I的杂环丙烯酰胺， 其中Het、X、Ra、Rb、R1、R2和R3具有权利要求中所示的含义，这些化合物调节内皮型一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体地，式I的化合物上调内皮型一氧化氮合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备式I化合物的方法，包括它们的药物组合物，以及利用式I化合物制造用于刺激内皮型一氧化氮合酶表达或治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等。
• Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
  申请人：sanofi-aventis

  公开号：EP1939181A1

  公开（公告）日：2008-07-02

  The present invention relates to heteroaryl-substituted carboxamides of the formula I, in which Het, A, X, R1, R2 and R3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及公式I的杂环取代羧酰胺，其中Het、A、X、R1、R2和R3具有索引中指示的含义，这些化合物调节内皮一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体地，公式I的化合物上调内皮一氧化氮合酶酶的表达，并可应用于需要增加该酶的表达或增加NO水平或正常化降低的NO水平的情况。该发明还涉及公式I化合物的制备方法，包括它们的药物组合物，以及公式I化合物用于制造刺激内皮一氧化氮合酶表达或治疗各种疾病的药物的用途，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等。
• HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS
  申请人：STROBEL Hartmut

  公开号：US20100016272A1

  公开（公告）日：2010-01-21

  The present invention relates to heteroarylacrylamides of the formula I, in which Het, X, R a , R b , R 1 , R 2 and R 3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及式I的杂环基丙烯酰胺，其中Het、X、Ra、Rb、R1、R2和R3具有声明中指示的含义，这些化合物调节内皮型一氧化氮（NO）合成酶的转录，是有价值的药理活性化合物。具体来说，式I的化合物上调内皮型NO合成酶的表达，可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备式I的化合物的过程，包括它们的制药组合物，以及使用式I的化合物制造用于刺激内皮型NO合成酶表达或治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化，血栓形成，冠状动脉疾病，高血压和心脏功能不全等。
• HETEROARYL-SUBSTITUTED CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS
  申请人：STROBEL Hartmut

  公开号：US20100016337A1

  公开（公告）日：2010-01-21

  The present invention relates to heteroaryl-substituted carboxamides of the formula I, in which Het, A, X, R 1 , R 2 and R 3 have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及公式I的杂环取代羧酰胺，其中Het、A、X、R1、R2和R3在权利要求中所示，它们调节内皮型一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体来说，公式I的化合物上调内皮型一氧化氮合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或恢复降低的NO水平的情况。本发明还涉及制备公式I化合物的方法，包括它们的制药组成物，以及公式I化合物用于制造用于刺激内皮型NO合酶表达或治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心力衰竭等。
• HETEROARYL-SUBSTITUTED CARBOXAMIDES AND USE THEREOF FOR THE STIMULATION OF THE EXPRESSION OF NO SYNTHASE
  申请人：Sanofi-Aventis

  公开号：EP2097382A1

  公开（公告）日：2009-09-09